AxoGen Wins BLA for Avance
AxoGen said its Avance product secured a Biologics License Application approval for peripheral nerve repair, which the company argues will strengthen coverage talks and reimbursement momentum, announced. That regulatory win immediately shifts AxoGen’s commercial leverage when negotiating payer coverage for nerve‑repair treatments.
AxoGen announcedir.axogeninc.com FDA approval of AVANCE (acellular nerve allograft–arwx) on Dec. 3, 2025, formally moving the product from its historical human‑tissue classification into a licensed biologic.ir.axogeninc.com The FDA license authorizes traditional approval for sensory nerve gaps ≤25 mm and grants Accelerated Approval for sensory gaps >25 mm as well as mixed and motor nerve discontinuities, with continued approval contingent on verification in confirmatory studies.fda.gov The approval letter mandates a prospective, randomized, assessor‑blinded, multicenter confirmatory trial (Protocol ANG‑CP‑013) that will compare AVANCE to sural‑nerve autograft using functional endpoints such as Medical Research Council motor and sensory classifications at Month 24.fda.gov Commercial availability of the licensed AVANCE product is slated for early in the second quarter of 2026 while Avance remains available under the current tissue framework until then.ir.axogeninc.com Axogen executives also cited recent balance‑sheet improvements and a focus on debt paydown during investor discussions tied to the regulatory milestone.marketbeat.com
